Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

In search of a treatment for Alzheimer’s Disease: Correlating molecular structure of novel unnatural amino acids to arginase inhibitory activity

EF 2021-22

Résumé
Alzheimers Disease (AD) is one of the deadliest diseases in our population and it currently has no known treatments. To advance the search for a treatment, I am synthesizing and studying novel inhibitors of arginase, the enzyme that breaks down arginine amino acids in the brain. Arginase inhibitors have shown therapeutic potential, as their use in mouse AD models improved their memory and cognition, but current inhibitors are not potent enough for human use. By synthesizing and studying novel inhibitors, I will identify characteristics of potent arginase inhibitors, which can aid in future drug development and is the primary objective of my study.Using synthetic organic chemistry, I will synthesize20 novel molecules with known properties of arginase inhibitors. I will determine each molecule's chemical structure using nuclear magnetic resonance and mass spectrometry. Then, I will measure each molecule's potency of inhibition using an arginase assay. The assay will indicate each compounds IC50, which is the drug concentration at which 50% of arginase enzymes are inhibited. IC50 values will be correlated to molecular structure to determine characteristics most strongly correlated with potent inhibition. Identified characteristics will direct subsequent rounds of synthesis until a compound with an IC50 below 1µM is made, which can then undergo further drug development testing.Characterizing potent inhibitors will guide the development of arginase inhibitors and help improve the potency of the compounds. The development of more potent arginase inhibitors gives them the potential to be used as therapeutic agents. By doing so, these novel therapeutics can alleviate the suffering experienced by those living with AD and allow them to lead a more meaningful life.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
466560
Name
Lagace Nicole C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
In search of a treatment for Alzheimer’s Disease: Correlating molecular structure of novel unnatural amino acids to arginase inhibitory activity
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Arginase; Arginine; Drug Development; Inhibitors; Qsar
Abstract
Alzheimers Disease (AD) is one of the deadliest diseases in our population and it currently has no known treatments. To advance the search for a treatment, I am synthesizing and studying novel inhibitors of arginase, the enzyme that breaks down arginine amino acids in the brain. Arginase inhibitors have shown therapeutic potential, as their use in mouse AD models improved their memory and cognition, but current inhibitors are not potent enough for human use. By synthesizing and studying novel inhibitors, I will identify characteristics of potent arginase inhibitors, which can aid in future drug development and is the primary objective of my study.Using synthetic organic chemistry, I will synthesize20 novel molecules with known properties of arginase inhibitors. I will determine each molecule's chemical structure using nuclear magnetic resonance and mass spectrometry. Then, I will measure each molecule's potency of inhibition using an arginase assay. The assay will indicate each compounds IC50, which is the drug concentration at which 50% of arginase enzymes are inhibited. IC50 values will be correlated to molecular structure to determine characteristics most strongly correlated with potent inhibition. Identified characteristics will direct subsequent rounds of synthesis until a compound with an IC50 below 1µM is made, which can then undergo further drug development testing.Characterizing potent inhibitors will guide the development of arginase inhibitors and help improve the potency of the compounds. The development of more potent arginase inhibitors gives them the potential to be used as therapeutic agents. By doing so, these novel therapeutics can alleviate the suffering experienced by those living with AD and allow them to lead a more meaningful life.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lagace, Nicole C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~